OptiBiotix Health PLC Notice of General Meeting of Warrant Holders (6696S)
23 December 2016 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 6696S
OptiBiotix Health PLC
23 December 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Notice of General Meeting of Warrant Holders
OptiBiotix Health plc (AIM: OPTI), announces that it will today
be posting a circular to holders of the warrant instruments dated
28 January 2014 and 19 February 2014 (the "Warrant Instruments")
comprising notice of two separate general meetings of warrant
holders to be held at Jeffrey's Henry, 5-7 Cranwood Street, London,
EC1V 9EE on 24 January 2017 at 11:00 am and 12:00 noon respectively
(the "Meetings"), and deeds of variation (the "Deeds") for the
respective Warrant Instruments.
The Meetings have been convened to propose variations of certain
terms of the Warrant Instruments, extending their respective long
stop dates from the second anniversary of the date of each Warrant
Instrument to the eighth anniversary of the date of each Warrant
Instrument. If approved, the new long stop dates for each of the
Warrant Instruments would be 28 January 2022 and 19 February 2022
respectively.
Adam Reynolds, a director of the Company, is a holder of the
Warrant Instruments and as such the variation of the Deeds will be
deemed to be a related party transaction. Pursuant to AIM Rule 13,
the directors of the Company, having consulted with its nominated
adviser believe the terms to be fair and reasonable as far as
shareholders are concerned.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP Tel: 020 7213 0880
Liam Murray
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate
Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOGUUSWRNAAUUAA
(END) Dow Jones Newswires
December 23, 2016 02:00 ET (07:00 GMT)